Extended Data Fig. 1: Tumour glycolysis and immune cell function.
From: CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
a, Quantification of glucose and lactate by 1H-NMR in supernatants from 72 h cultures of activated T cells (100,000 cells), 4T1 cells (3,000 cells) and the two cell types together. Plots show combined results from two independent experiments (n = 2 per experiment). b, Percentage of proliferating (CFSElow) (left) and dead (right) CD4+ or CD8+ T cells assessed by flow cytometry after 48 h activation in the presence of the indicated concentrations of lactic acid to define the workable lactate dose range (n = 3 per condition, except for 0 μM lactic acid, n = 2). c, d, Flow cytometry analysis of the indicated parameters in CD8+ and CD4+ T cells activated for 48 h in the presence or absence of 4T1 cells (c) or of 10 mM lactate (d) from two independent experiments (n = 3). e, f, Expression of immune cell signatures by CIBERSORT (top) and glycolysis-related genes (bottom) in RNA-seq datasets from human melanoma samples at baseline (e, n = 7) and after ipilimumab treatment (f, n = 15). Each column in the heat maps represents an independent tumour sample. Data are mean ± s.d. P values determined by two-sided unpaired t-test.
